drugset / Trial / NCT04667143
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
2 weeks screening period, 4 weeks run-in period, 24 weeks double-blind treatment period, to evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein added to Metformin compared to Retagliptin or Henagliflozein in combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone
Timeline
- Start
- 2021-01
- Primary completion
- 2022-09
- Completion
- 2022-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Henagliflozein | Unknown | 5 mg | — |
| Subject | Henagliflozein | Unknown | 10 mg | — |
| Subject | Retagliptin | Small molecule | 100 mg | — |
| Background | Metformin | Small molecule | — | — |